EXCLUSIVE: FibroBiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial for Diabetic Foot Ulcers; CYWC628 Is Multicenter Phase 1/2 Clinical Study of Fibroblast Cell Therapy In Australia

Benzinga Newsdesk www.benzinga.com Neutral 57.4%

Neg 0% Neu 57.4% Pos 0%

Comments

No comments yet. Be the first!